Evaluation of a Screening Strategy of Fabry Disease in Patient With Renal Biopsy

NCT03869554 | Recruiting

• 1 other identifier: 49RC19_0032
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Fabry disease is genetic X linked disease, with annual incidence of 1 in 100,000 that is certainly underestimate the true prevalence of the disease. Renal biopsy in some patients does not allow determining the etiology of nephropathy. It is why investigators would like to evaluate the screening of Fabry patients from renal biopsy in patient with idiopathic nephropathy. Investigator hypothesize to detect one or more cases of patients with Fabry disease in local idiopathic nephropathy population with renal biopsy. That would allow reviewing and optimizing the target screening for Fabry Disease. The purpose would be to detect Fabry disease systematically in patients presenting a nephropathy of undetermined etiology in spite of the renal biopsy or presenting nonspecific histological characteristics. In Fabry disease with renal impairment, proteinuria is the first sign, usually occurring in the second decade. The evolution is progressively towards end-stage renal failure during the fourth decade. The presence of renal impairment is globally associated with a poor prognosis. Renal histology can be used to diagnose Fabry disease by revealing sphingolipid deposits identified by optical microscopy in the form of vacuoles in podocytes, distal tubule epithelial cells or in the media of the distal tubules. vascular walls. Resin inclusion with Toluidine blue staining is the staining of choice for visualizing lipid inclusions. However, this staining is not used as a first intention in routine. On the paraffin-fixed tissues, the vacuoles are less visible because they dissolve. Thus, the renal histological analysis sometimes reveals only non-specific damage to the various structures of the kidney and may not allow identification of very evocative inclusions. Under the effect of oxidative stress induced by sphingolipid deposits, lesions of tubulo-interstitial fibrosis settle quite early. At the level of the glomerulus, glycosphingolipids lead to the production of angiotensin II and TGF-β leading to an excess production of constituents of the glomerular basement membrane inducing its thickening and glomerulosclerosis. Arteries of all sizes are also the seat of intimal thickening and media accelerating the process of intrarenal ischemia. These lesions, which may appear isolated or synchronous, and nonspecific, are sometimes in the foreground and do not point in the first line to the etiological diagnosis of Fabry disease. Also, among the patients presenting a nephropathy of undetermined etiology in spite of the renal biopsy or presenting nonspecific histological characteristics, investigator propose to systematically detect the Fabry disease. Screening will be done in a selected population of renal biopsy patients using the dried blood spot kits.

Conditions

Renal Disease

Outcome Measures

Primary Outcomes (1)

• Assess the value of screening for Fabry's disease in patients with kidney disease whose etiology remains undetermined after renal biopsy

  number of patients diagnosed with Fabry's disease identified

  1 month

Secondary Outcomes (1)

• Estimate the prevalence of Fabry disease

  12 months

Study Arms (1)

Renal disease

EXPERIMENTAL

detection of Fabry disease

Diagnostic Test: Detection of Fabry disease

Interventions

Detection of Fabry disease DIAGNOSTIC_TEST

Systematic detection of Fabry disease

Renal disease

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult patient (\> 18 years old)
• Obtaining consent to participate in the study
• Patients whose clinical presentation meets at least one of the following criteria:
• Undetermined nephropathy despite renal biopsy,
• Nephroangiosclerosis as the predominant lesion
• Chronic tubulointerstitial nephropathy,
• Glomerulosclerosis,
• Segmental and focal hyalinosis.
• Optically normal kidney or seat of minimal lesions

You may not qualify if:

• Patient who has already been screened for Fabry Disease
• At least one of the following criteria:
• Nephrotic syndrome and/or Glomerular nephropathy
• Histological diagnosis of certain nephropathies (specific kidney lesions)

Sponsors & Collaborators

• University Hospital, Angers: lead

Study Sites (1)

CHU Angers

Angers, France

RECRUITING

MeSH Terms

Conditions

Kidney Diseases

Condition Hierarchy (Ancestors)

Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Central Study Contacts

Jean-François AUGUSTO

CONTACT

02 41 35 82 02; jfaugusto@chu-angers.fr

Béatrice GABLE

CONTACT

0241356825; begable@chu-angers.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 7, 2019
• First Posted: March 11, 2019
• Study Start: February 3, 2020
• Primary Completion: June 2, 2025
• Study Completion: August 2, 2025
• Last Updated: June 11, 2024

Record last verified: 2024-06

Locations

FR (1)